zoledronic acid has been researched along with Albers-Schoenberg Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bhadada, SK; Dhiman, V; Gopinathan, NR; McAlister, WH; Whyte, MP | 1 |
| Chatani, M; Inoue, M; Isawa, M; Karakawa, A; Kuritani, M; Negishi-Koga, T; Nishina, S; Sakai, N; Sato, M; Shimada, Y; Takami, M | 1 |
| Grasko, JM; Herrmann, RP; Vasikaran, SD | 1 |
| Anginot, A; Blin-Wakkach, C; Carle, GF; Mancini, SJ; Mansour, A; Schiff, C; Wakkach, A | 1 |
| Amann, K; Hyckel, P; Neukam, F; Nkenke, E; Ries, J; Schlegel, K; Stockmann, P; Wehrhan, F | 1 |
| Tanvetyanon, T | 1 |
| Broumand, V; Fortin, M; Marx, RE; Sawatari, Y | 1 |
7 other study(ies) available for zoledronic acid and Albers-Schoenberg Disease
| Article | Year |
|---|---|
Drug-induced osteopetrosis.
Topics: Child; Fractures, Bone; Humans; Osteoclasts; Osteopetrosis; Skull; Zoledronic Acid | 2023 |
Biological Effects of Anti-RANKL Antibody and Zoledronic Acid on Growth and Tooth Eruption in Growing Mice.
Topics: Animals; Animals, Newborn; Antibodies; Humans; Mice; Osteoblasts; Osteoclasts; Osteopetrosis; RANK Ligand; Rats; Tooth Eruption; Zoledronic Acid | 2019 |
Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates.
Topics: Bone Density Conservation Agents; Cross Infection; Diphosphonates; Escherichia coli Infections; Fatal Outcome; Femoral Fractures; Fractures, Spontaneous; Humans; Imidazoles; Injections, Intravenous; Male; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Recurrence; Zoledronic Acid | 2009 |
Osteoclast activity modulates B-cell development in the bone marrow.
Topics: Animals; B-Lymphocytes; Bone and Bones; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Cells; Cell Proliferation; Cells, Cultured; Chemokine CXCL12; Diphosphonates; Female; Imidazoles; Interleukin-7; Lymphopoiesis; Mice; Mice, Inbred BALB C; Osteoclasts; Osteopetrosis; Stromal Cells; Zoledronic Acid | 2011 |
Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.
Topics: Alkaline Phosphatase; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 4; Bone Remodeling; Cell Count; Diphosphonates; Fibroblasts; Humans; Imidazoles; Immunohistochemistry; Jaw Diseases; MSX1 Transcription Factor; Osteoblasts; Osteocytes; Osteonecrosis; Osteopetrosis; Pamidronate; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Zoledronic Acid | 2011 |
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Topics: Analgesics; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Jaw; Male; Necrosis; Osteomyelitis; Osteopetrosis; Pain; Pain Measurement; Pamidronate; Prostatic Neoplasms; Quality of Life; Research Design; Surveys and Questionnaires; Time Factors; Treatment Outcome; Zoledronic Acid | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Dental Caries; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hyperostosis; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Osteoporosis; Pamidronate; Periodontitis; Prostatic Neoplasms; Risk Factors; Tooth Extraction; Zoledronic Acid | 2005 |